MedTrace Logo

The Sublimated Mare Milk Supplement in Hepatitis C

NCT03669835 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-02-08

No results posted yet for this study

Summary

This clinical trial studies the effect of sublimated mare milk supplement on patients with hepatitis C.

Conditions

  • Hepatitis C

Interventions

DIETARY_SUPPLEMENT

Mare milk supplement

Supplement consisting of sublimated mare's milk with single-dose 20 mg sachet. The supplement is dissolved in 36-27 degrees of Celsius water and taken 15-20 minutes before meal.

DRUG

Standard therapy

For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.

Sponsors & Collaborators

  • Eurasia Invest Ltd.

    collaborator INDUSTRY

  • Ministry of Education and Science, Republic of Kazakhstan

    collaborator OTHER_GOV

  • Asfendiyarov Kazakh National Medical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-28
Primary Completion
2019-09-20
Completion
2020-12-01

Countries

  • Kazakhstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03669835 on ClinicalTrials.gov